Corresponding Author: Alyce S. Adams, PhD, 2000 Broadway, Oakland, CA, USA 94612; ph: 1-510-891-5921; fax: 1-510-891-3606; Alyce.S.Adams@kp.org. 1.) Contributors: The authors would like to thank Dr. Christine Bishop at the Heller School for Social Policy and Management at Brandeis University for facilitating access to data from the Centers for Medicare and Medicaid Services. In addition, we would like to acknowledge Dr. Andrea Altschuler at Kaiser Permanente Division of Research, PhD, Ms. Angelina Lee and Dr. Meredith Chace, PhD, at JEN Associates, Inc., and Ms. Rosa Hippler, MA, at Kaiser Permanente Division of Research for assistance with project management, data collection, data verification and editing. We are indebted to Drs. Joseph P. Newhouse at the Department of Health Care Policy at Harvard Medical School and Larissa Nekhlyudov at the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute for lending their advice and comments on an earlier version of this manuscript. Written permission has been obtained from each of these individuals.
INTRODUCTION
Diabetes affects more than 25 million Americans, costs an estimated $245 billion per year in health care costs and lost productivity, and is a major contributor to racial and ethnic disparities in morbidity and mortality. (1, 2) More than half of adults with diabetes have at least one other chronic physical or mental health condition. (3) Depression is one of the most prevalent comorbidities, with an estimated 20% of adult diabetes patients suffering from major depression. (4) Comorbid depression is independently associated with poorer outcomes among individuals with diabetes.(5-7) Identifying and treating depression has become an increasingly important component of diabetes management. (8) While antidepressant medications are highly effective tools in the co-management of depression among adults with diabetes, rates of pharmacologic treatment of depression remain suboptimal and are especially low among African Americans. (9, 10) studies suggest that African Americans may be at greater risk for cost-related non-adherence and that reducing economic barriers to prescription drugs may reduce disparities in adherence to chronic disease medications. (15, 16) Natural experiments that increase economic access to prescription drugs provide a unique opportunity to evaluate the degree to which such policy changes may reduce disparities in antidepressant treatment among diabetes patients.
When Medicare Part D was implemented as an outpatient prescription benefit for Medicare enrollees in 2006, seven million people who were dually enrolled in both Medicare and Medicaid due to permanent disability or low income were automatically transitioned from Medicaid drug coverage to Part D. (17, 18) For dual enrollees living in states with strict caps on the number of reimbursable prescriptions per month (drug caps), the transition to Part D, which disallowed drug caps, eliminated a significant financial barrier to drug treatment. (19) Our central research question was whether the transition to Part D increased antidepressant treatment rates among dual enrollees with diabetes and depression living in states with strict drug caps at the time of the transition relative to those living in states without drug caps. Secondarily, we examined whether there were differences in response by race, in order to assess the potential for such policies to reduce disparities in antidepressant treatment among diabetes patients.
We hypothesized that the transition would increase overall rates of treatment of depression and reduce the racial disparity in antidepressant use. The findings from this study are highly relevant as newly eligible dual enrollees continue to transition from states with restrictive drug caps to Medicare Part D on an ongoing basis following the two-year waiting period for Medicare eligibility. In addition, they have the potential to inform evaluation of Medicaid coverage expansion under the Affordable Care Act and the need to assess the impact of the ACA on disparities populations. Specifically, the findings from this study provide information about the potential for reducing out-of-pocket costs for medications as a strategy to address under-treatment among patients with diabetes and as a mechanism to reduce racial disparities in depression treatment.
RESEARCH DESIGN AND METHODS
We used an interrupted time series with comparison series (ITS) design to examine changes in the monthly rate of antidepressant treatment for 24 months before and after the transition of dual enrollees from Medicaid to Medicare Part D drug coverage. This quasi-experimental design provides strong evidence of the immediate and ongoing effects of Part D on antidepressant treatment among diabetes patients with comorbid depression.
Our study protocol was reviewed and approved by the Institutional Review Board of the Kaiser Foundation Research Institute.
Data Sources and Study Population
We used a 5% nationally representative sample of dual Medicare and Medicaid enrollees provided by the Centers for Medicare and Medicaid Services. These data contain all health insurance claims and enrollment data between January 2004 and December 2007. (20, 21) Using these data, we identified a cohort of fee-for-service dual beneficiaries who were at least 18 years old in 2004 and who had at least one hospital diagnosis or two physician diagnoses (no more than 12 months apart) of diabetes (International Classification of Diseases, ICD9: 250.XX) (22) at any time during the study period (2004) (2005) (2006) (2007) . We excluded enrollees residing in Ohio, Arizona, and Louisiana due to data anomalies such as concurrent changes in coding and reporting methods. (23) The resulting population included 60,288 adults with diabetes.
In order to ensure stable population characteristics over time and complete data on utilization, we also required continuous enrollment for at least 10 months per year in fee-forservice Medicaid and Medicare during the study period (n=29,373) and excluded patients with more than 90 consecutive days in any year in an institution such as a nursing home (n=22,774).
Drug Reimbursement before Part D
We assigned strict drug cap status to four states (Texas, Oklahoma, Mississippi, Arkansas) that consistently limited monthly drug coverage to five or fewer total prescriptions or to three or fewer brand name drugs during the 24-month baseline period [2004] [2005] . We excluded from analysis 11 states where true exposure to or enforcement of drug caps was uncertain. For example, some states required caps, but allowed for exceptions for chronic disease medications. We conducted sensitivity analysis to assess the impact of excluding these 11 states and found that rates of medication use in the excluded states mimicked those of the no drug cap group. In addition, we excluded Tennessee, which instituted a strict drug cap late in the baseline period. (24) We identified a comparison subgroup of dual enrollees who lived in 31 states (AK, CO, CT, DE, FL, HI, IA, ID, IN, MA, MD, MI, MN, MO, MT, ND, NE, NH, NJ, NM, NV, OR, RI, SD, UT, VA, VT, WA, WI, WV, WY) and the District of Columbia where there were no prescription drug caps during the 24-month baseline period. The strict drug cap and no drug cap states included 10,992 adults diagnosed with diabetes. Enrollees in our sample were similar to the overall fee-for-service dual enrollee population at the time with respect to race and ethnicity distribution, but slightly more likely to be under 65 (40% vs. 36%) and female (70% vs. 62%). (25) 
Comorbid Major Depression
Within the cohort of 10,992 adult dual enrollees with diabetes, we identified a subset of people with evidence of major depression, defined as having at least one hospital or two physician visits with a diagnosis of major depression. (26) The resulting 1,354 dual enrollees with diabetes and comorbid major depression, representing 27,080 dual enrollees, served as the analytic cohort for this paper. (Figure 1 )
Outcomes
Our primary outcomes were (1) the monthly proportion of patients with any use of antidepressants, including tricyclics, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, serotonin modulators, and selective norepinephrine reuptake inhibitors, and (2) the intensity of use of these medications as represented by standardized monthly doses. To assess intensity of use, we first defined a standardized monthly dose (SMD) (27, 28) for each unique molecular entity of interest, which was equal to the median number of milligrams dispensed per month across person-months with any use during the entire study period. Thus, SMDs represent the population's "typical" monthly dose for a given medication in this population. We then calculated average SMDs dispensed per patient per month across all antidepressant medications.
Policy Variables
We controlled for prior trends in the outcomes of interest using segmented time series regression, as described in previous studies. (19, 27, (29) (30) (31) We included a dichotomous indicator for months before and after Part D implementation, as well as a variable to estimate changes in post-Part D trends. We identified state drug cap status in 2005 (strict drug cap vs. no drug cap) using a dichotomous indicator. We then estimated the effect of Part D within strict cap and no cap states, separately.
Covariates
We used Medicare administrative files to determine racial identity, age, and gender. Given higher rates of long-term disability among younger dual enrollees, we stratified all analyses by age: aged 65 or older (elderly) versus 18-65 years of age (non-elderly). Only black and white dual enrollees are included in this analysis due to the lack of sensitivity and specificity for other racial and ethnic categories during the study period. (32, 33) 
Statistical Analysis
We used interrupted time series (ITS) with comparison series to evaluate changes from baseline in the level and trend of antidepressant use. (30) Segmented regression analysis of interrupted time series data allowed us to evaluate the immediate discontinuity and longer term slope change in medication after the introduction of Part D. In these models, potential confounding was limited to factors that were both correlated with the outcome and that changed at the same time as the intervention. Therefore, factors that changed gradually over time such as age, education, income and comorbidity were not potential confounders and were not included in the regression models. (30) We first estimated the overall impact of transitioning to Part D by cap status using separate ITS models for dual enrollees with major depression in strict drug cap and no drug cap states. To control for anticipatory effects of the policy (e.g., changes in prescribing practices) and the phase-in period of the transition, we excluded the observations between December 2005 and March 2006. Our time series models controlled for autocorrelation by testing for first-order autoregressive processes and correcting for significant correlations. We also tested for non-linearity of the models. (30) We next examined changes in rates of antidepressant use and in intensity of use, stratifying by black and white race within non-elderly (under 65) and elderly (65+) subgroups. We then directly evaluated the impact of Part D on racial gaps in treatment by modeling the monthto-month white-black difference in use within age strata.
All statistical analyses were conducted using the SAS system (SAS, v.9.0, Durham, NC). (34) Table 1 examines the characteristics of dual enrollees with diabetes at baseline (2005) overall and compares demographic characteristics between patients with and without evidence of diabetes and comorbid major depression during the study period. Dual enrollees with a major depression diagnosis were more likely to be white, under the age of 65, and female compared to those without concurrent depression. In addition, those with diagnoses of comorbid major depression were more likely to be living in states without drug caps prior to Part D.
RESULTS

Baseline Characteristics by Depression Status
Impact of Part D on Antidepressant Use in States with and without Drug Caps
At baseline (Table 2) , the proportion using antidepressants in states without drug caps was more than twice that for an equivalent population of dual enrollees living in strict cap states. 
Racial Differences in Antidepressant Use Pre and Post Policy in Cap States
Prior to the policy change, the observed proportion of depressed patients using antidepressants in strict cap states was half as much for blacks compared to whites.( Figure  3A Changes in the intensity of use by race are presented in Figure 3B and Table 3 
DISCUSSION
Among dual enrollees with diabetes and comorbid major depression living in states with drug caps, we observed a modest increase in the proportion using antidepressants and in the intensity of antidepressant use after the transition to Part D. The absence of a corresponding increase in use in non-drug cap states is consistent with our hypothesis that the removal of drug caps under Part D would be associated with an increase in access to antidepressant therapy. However, we also observed an unexpected increase in the racial gap in antidepressant use among dual enrollees with diabetes and major depression in strict drug cap states immediately following Part D implementation that was driven by a greater response to the policy among non-elderly whites.
Two previous studies of Part D effects reported no changes in medication use associated with Part D among elderly dual enrollees. (35, 36) Differences between our work and previous studies of changes in utilization may be explained by our focus on those living in states with strict drug caps. In addition, we observed a slight decrease in use within non-drug cap states; combining all dual enrollees without regard to coverage changes would lead to a conclusion of no change at the population level.
To our knowledge, our study is the first to show an increase in the racial gap in antidepressant treatment associated with Medicare Part D implementation. In a related study, we reported that Part D was equally effective in increasing the use of lipid lowering medications among black and white dual enrollees with diabetes.(37) The reasons for differential response to coverage expansion are likely multifactorial. One possible explanation for this difference is that use among African Americans may be driven by nonfinancial factors to a greater extent than it is among whites.. (38) For example,, several studies have reported cultural differences in preferences for mental health treatment and illness-related beliefs that may contribute to reduced price sensitivity among African Americans. (3, 11) In addition, differences in knowledge of coverage changes, may also contribute to the observed differential policy response.(39) For example, Haviland and colleagues reported that African Americans, Hispanics and Asian Pacific Islanders were all more likely to report lack of knowledge about Part D plan coverage. (40) More studies are needed to identify the potential mechanisms for differential response in order to identify mediating factors that are potentially modifiable through health system intervention (e.g., knowledge gaps).
This quasi-experimental study has some limitations that deserve consideration. During the study period, there were other changes in Medicaid and Medicare coverage and utilization management that may have contributed to the observed changes. By our design, we focused on a population of dual enrollees who experienced a substantial change in exposure to drug caps for simplicity of analysis and because caps are known to have especially strong effects. (9, 27, 29) We limited analysis to enrollees who had evidence of major depression during the study period. Since antidepressants may be used for other indications, this allowed us to focus on a more homogenous population. However, our findings may apply to the treatment of milder forms of depression as well that are not as reliably identified in claims data. In addition, with the exception of black and white dual enrollees, race and ethnicity data in Medicaid are generally unreliable for the period of this study. As a result, we did not include subgroups other than blacks and whites in our comparison of race differences in use, nor could we accurately exclude dual enrollees of Hispanic origin from our comparisons. Therefore, there may have been additional variation in response in these subgroups that we failed to capture. Allowing beneficiaries to have a diagnosis at any time during the study period means that some patients included in the denominator at any given time may have been ineligible for treatment. However, this error should be distributed equally across subgroups of patients and change gradually over time, and is therefore unlikely to have introduced bias in our findings. Finally, our observations of a study population living in selected states with substantial financial barriers in Medicaid drug coverage do not necessarily reflect the experience of the entire dual enrollee population.
CONCLUSION
Depression is frequently undertreated among patients with diabetes and African Americans may be at higher risk for under-treatment of this high cost and potentially disabling comorbidity.(9,10) Inadequate medication coverage poses a significant barrier to treatment for many patients, particularly low income Medicaid beneficiaries. (12) (13) (14) In this natural experiment, we demonstrated the potential for expanded drug coverage to improve rates of antidepressant use. However, coverage expansions may also have the unintended consequence of widening racial disparities in antidepressant treatment. The ongoing transition of dual enrollees from state Medicaid drug coverage to Medicare Part D programs following a two-year waiting period may perpetuate these disproportionate impacts in certain states.(18) At a minimum, federal and state health systems leaders should be aware of the potential for unintended effects of coverage expansions for disparities reduction. Interventions at the point of care may be needed to counteract these effects through increased education and outreach to African Americans with diabetes about the importance of depression treatment as a component of diabetes care. Description of the application of inclusion and exclusion criteria and impact on sample size. 
